Azienda Ospedaliero-Universitaria Meyer

Florence 50139

3 studies enrolling now · 12 studies all time

What they study most

AB Variant Gangliosidosis GM2, ALK-positive Histiocytosis, Anesthesia, COVID-19, Child Development, Cyclin-Dependent Kinase-Like 5 Deficiency Disorder, Epilepsy, Partial Seizures, Epilepsy, Primary Generalized Tonic-Clonic Seizures, Erdheim-Chester Disease (ECD), GM1 Gangliosidosis, GM2 Gangliosidosis, Gaucher Disease, Type 2

Studies at this site

• A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities — Recruiting now
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) — Recruiting now
• Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH) — Recruiting now
• International Rare Histiocytic Disorders Registry (IRHDR) — Recruiting now
• A Study to Compare the Long-term Outcomes After Two Different Anaesthetics — Running, not enrolling
• Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency Disorder — Running, not enrolling
• Study of Remdesivir in Participants Below 18 Years Old With COVID-19 — Completed
• Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis — Completed
• A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes — Completed
• Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2 — Completed
• A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years — Completed
• A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures — Completed